Business Context and Reporting Period
Adagio Therapeutics, Inc. filed a Form 8-K dated June 24, 2022, under Item 5.02 regarding a change to its board of directors. The company’s common stock traded under the symbol ADGI on Nasdaq. The filing was signed June 30, 2022.
Key Financial Metrics
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes
- Howard Mayer, M.D. resigned from the company’s board of directors and all board committees, effective immediately on June 24, 2022.
- The filing states that Dr. Mayer’s resignation was not due to any disagreement with the company regarding its operations, policies, or practices.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, operating outlook, contingencies, or additional risk disclosures. The board resignation is the only reported event.
Investor Verification Points
- Verify the effective date of Dr. Mayer’s resignation and the resulting composition of the board and its committees.
- Review subsequent filings for any replacement director, committee changes, or related governance actions.
- Confirm whether later company filings reflect a corporate name or ticker change from Adagio Therapeutics, Inc. and ADGI.